Leerink Swann reiterated their outperform rating on shares of Celgene Corporation (NASDAQ:CELG) in a research report sent to investors on Friday morning. They currently have a $160.00 price objective on the biopharmaceutical company’s stock, up from their previous price objective of $150.00.

A number of other brokerages have also issued reports on CELG. Mizuho set a $134.00 target price on shares of Celgene Corporation and gave the company a buy rating in a research report on Wednesday, July 26th. Cantor Fitzgerald set a $160.00 target price on shares of Celgene Corporation and gave the company a buy rating in a research report on Thursday, July 27th. Robert W. Baird reiterated an outperform rating and issued a $162.00 target price on shares of Celgene Corporation in a research report on Friday, July 21st. Zacks Investment Research upgraded shares of Celgene Corporation from a hold rating to a buy rating and set a $151.00 target price for the company in a research report on Tuesday, July 18th. Finally, SunTrust Banks, Inc. reiterated a buy rating and issued a $150.00 target price on shares of Celgene Corporation in a research report on Friday, July 14th. One analyst has rated the stock with a sell rating, six have given a hold rating and twenty-three have given a buy rating to the stock. Celgene Corporation has an average rating of Buy and a consensus price target of $146.02.

Shares of Celgene Corporation (NASDAQ CELG) opened at 135.41 on Friday. Celgene Corporation has a one year low of $96.93 and a one year high of $139.00. The stock has a market cap of $105.94 billion, a P/E ratio of 41.94 and a beta of 1.89. The stock has a 50 day moving average of $131.55 and a 200 day moving average of $123.19.

Celgene Corporation (NASDAQ:CELG) last released its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.61 by $0.21. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The business had revenue of $3.27 billion for the quarter, compared to analysts’ expectations of $3.23 billion. During the same quarter last year, the company earned $1.44 EPS. The company’s revenue for the quarter was up 18.7% compared to the same quarter last year. Equities analysts expect that Celgene Corporation will post $7.32 EPS for the current fiscal year.

WARNING: “Celgene Corporation (NASDAQ:CELG) Stock Rating Reaffirmed by Leerink Swann” was reported by Watch List News and is the property of of Watch List News. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://www.watchlistnews.com/celgene-corporation-nasdaqcelg-stock-rating-reaffirmed-by-leerink-swann/1465198.html.

In other news, Director James J. Loughlin sold 18,500 shares of the firm’s stock in a transaction on Monday, June 26th. The shares were sold at an average price of $133.57, for a total value of $2,471,045.00. Following the sale, the director now owns 32,877 shares in the company, valued at $4,391,380.89. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Rupert Vessey sold 4,785 shares of the firm’s stock in a transaction on Thursday, June 15th. The stock was sold at an average price of $120.18, for a total transaction of $575,061.30. Following the completion of the sale, the insider now owns 4,004 shares in the company, valued at approximately $481,200.72. The disclosure for this sale can be found here. In the last 90 days, insiders sold 227,755 shares of company stock worth $30,368,142. 0.95% of the stock is currently owned by corporate insiders.

Large investors have recently made changes to their positions in the company. RB Capital Management LLC acquired a new stake in Celgene Corporation during the fourth quarter worth $227,000. Pinnacle Financial Partners Inc. increased its stake in Celgene Corporation by 71.0% in the fourth quarter. Pinnacle Financial Partners Inc. now owns 12,466 shares of the biopharmaceutical company’s stock worth $1,443,000 after buying an additional 5,177 shares in the last quarter. Capital Guardian Trust Co. increased its stake in Celgene Corporation by 27.9% in the fourth quarter. Capital Guardian Trust Co. now owns 3,857 shares of the biopharmaceutical company’s stock worth $446,000 after buying an additional 841 shares in the last quarter. Clough Capital Partners L P increased its stake in Celgene Corporation by 133.1% in the fourth quarter. Clough Capital Partners L P now owns 135,676 shares of the biopharmaceutical company’s stock worth $15,704,000 after buying an additional 77,476 shares in the last quarter. Finally, Barings LLC increased its stake in Celgene Corporation by 31.4% in the fourth quarter. Barings LLC now owns 31,874 shares of the biopharmaceutical company’s stock worth $3,689,000 after buying an additional 7,620 shares in the last quarter. Institutional investors and hedge funds own 78.39% of the company’s stock.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Analyst Recommendations for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.